<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648817</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-104-0318</org_study_id>
    <secondary_id>EUDRACT Number: 2004-005083-25</secondary_id>
    <nct_id>NCT00648817</nct_id>
  </id_info>
  <brief_title>Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers</brief_title>
  <official_title>A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV-1 Seronegative Healthy Adult Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic changes commonly occur in HIV therapy. The purpose of this study is to assess the&#xD;
      impact on insulin sensitivity from the administration of tenofovir disoproxil fumarate 300 mg&#xD;
      compared with placebo in non-HIV-1 infected healthy adult males. Additionally, endothelial&#xD;
      function, adipocytokines and lipids will be monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, placebo-controlled study using a two-sequence two-period crossover&#xD;
      structure. Sixteen HIV-1-negative males will be randomized 1:1 to one of two treatment arms.&#xD;
&#xD;
      Group 1:&#xD;
&#xD;
        -  Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14&#xD;
           days of the study.&#xD;
&#xD;
        -  Tenofovir DF placebo tablet QD for the last 14 days of the study.&#xD;
&#xD;
      Group 2:&#xD;
&#xD;
        -  Tenofovir DF placebo tablet QD for the first 14 days of the study.&#xD;
&#xD;
        -  Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14&#xD;
           days of the study.&#xD;
&#xD;
      Physical examinations and laboratory analyses are conducted at screening, baseline, Day 14,&#xD;
      and Day 28. A euglycaemic clamp protocol and an ECG are performed at the baseline, Day 14 and&#xD;
      Day 28 visits.&#xD;
&#xD;
      The primary efficacy endpoint of this study is insulin-mediated glucose disposal during a&#xD;
      hyperinsulinaemic euglycaemic clamp study. Endothelial function will be monitored by Selectin&#xD;
      P/E and PAI-1 levels; adipocytokine levels will be monitored by measuring adiponectin and&#xD;
      leptin levels; and lipid subfractions, including cholesterol (large and small subfractions of&#xD;
      HDL and LDL) triglycerides and non-esterified fatty acids will be measured. Safety will be&#xD;
      evaluated by adverse event and clinical laboratory test reporting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the impact on insulin sensitivity (determined by peripheral glucose uptake suing a euglycaemic clamp) of the administration of tenofovir DF compared with placebo for two weeks in HIV-1 seronegative healthy male volunteers.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess endothelial function by monitoring changes in Selectin P/E and PAI-1 assays.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor adipocytokines by assessing adiponectin and leptin levels.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor lipids by assessing large and small lipoprotein sub-fractions of HDL and LDL cholesterol, triglycerides, and non esterified fatty acid concentrations.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.&#xD;
Tenofovir DF placebo tablet QD for the last 14 days of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir DF placebo tablet QD for the first 14 days of the study.&#xD;
Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF placebo</intervention_name>
    <description>Tenofovir DF placebo tablet QD</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have documented negative HIV serology by ELISA and P24 antigen. This&#xD;
             will be done at the screening visit.&#xD;
&#xD;
          -  Subjects must be clinically well males aged between 18 to 55 years.&#xD;
&#xD;
          -  Adequate renal function:&#xD;
&#xD;
          -  Calculated creatinine clearance (CrCl) &gt;= 100 mL/min according to the Cockcroft Gault&#xD;
             formula: Male: [(140 - age in years) x (actual body wt in kg)]/[72 x (serum creatinine&#xD;
             in mg/dL)]= CrCl (mL/min)&#xD;
&#xD;
          -  Fasting blood glucose, total cholesterol and triglycerides within normal limits&#xD;
&#xD;
          -  Hepatic transaminases (AST and ALT) &lt;= 3 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &lt;= 1.5 mg/dL&#xD;
&#xD;
          -  Adequate hematologic function (absolute neutrophil count &gt;= 1,000/mm3; platelets &gt;=&#xD;
             50,000/mm3; hemoglobin &gt;= 8.0 g/dL)&#xD;
&#xD;
          -  Serum amylase &lt;= 1.5 x ULN (subjects with serum amylase &gt; 1.5 x ULN will remain&#xD;
             eligible if pancreatic lipase is &lt;= 1.5 x ULN)&#xD;
&#xD;
          -  Serum phosphorus &gt;= 2.2 mg/dL&#xD;
&#xD;
          -  Sexually active males must use condoms&#xD;
&#xD;
          -  Life expectancy &gt;= 1 year&#xD;
&#xD;
          -  The ability to understand and sign a written informed consent form, which must be&#xD;
             obtained prior to initiation of study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a waist hip ratio &gt; 0.97 or BMI &gt; 28 kg/m2 will be excluded&#xD;
&#xD;
          -  Acute or chronic hepatitis B infection (determined by positive hepatitis B surface&#xD;
             antigen result at the screening visit)&#xD;
&#xD;
          -  Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody&#xD;
             result at the screening visit)&#xD;
&#xD;
          -  Other metabolic syndrome or disease process likely to cause marked disturbance in&#xD;
             glucose and lipid homeostasis&#xD;
&#xD;
          -  Receiving on-going therapy with any of the following:&#xD;
&#xD;
          -  Metabolically active medications&#xD;
&#xD;
          -  Any lipid-lowering medication&#xD;
&#xD;
               -  Hormonal agents (oestrogens or androgens)&#xD;
&#xD;
               -  Glucocorticoids&#xD;
&#xD;
               -  Beta-blockers&#xD;
&#xD;
               -  Thiazide diuretics&#xD;
&#xD;
               -  Thyroid preparations&#xD;
&#xD;
               -  Psychotropic agents&#xD;
&#xD;
               -  Anabolic steroids&#xD;
&#xD;
               -  Megoestrol acetate&#xD;
&#xD;
               -  Nephrotoxic agents&#xD;
&#xD;
                    -  aminoglycoside antibiotics&#xD;
&#xD;
                    -  IV amphotericin B&#xD;
&#xD;
                    -  cidofovir&#xD;
&#xD;
                    -  cisplatin&#xD;
&#xD;
                    -  foscarnet&#xD;
&#xD;
                    -  IV pentamidine&#xD;
&#xD;
                    -  other agents with significant nephrotoxic potential&#xD;
&#xD;
               -  Vancomycin&#xD;
&#xD;
               -  Oral or IV ganciclovir&#xD;
&#xD;
               -  Agents that inhibit or compete for elimination via active renal tubular secretion&#xD;
&#xD;
                  ** Probenecid&#xD;
&#xD;
               -  Systemic chemotherapeutic agents (i.e., cancer treatment medications)&#xD;
&#xD;
               -  Systemic corticosteroids&#xD;
&#xD;
               -  Interleukin 2 (IL 2) and other immunomodulating agents&#xD;
&#xD;
               -  Investigational agents&#xD;
&#xD;
        Administration of any of the above medications must be discontinued at least 30 days prior&#xD;
        to the baseline visit and for the duration of the study period.&#xD;
&#xD;
          -  Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting&#xD;
             which may confer an inability to receive an orally administered medication.&#xD;
&#xD;
          -  Current alcohol or substance abuse judged by the investigator to potentially interfere&#xD;
             with subject compliance.&#xD;
&#xD;
          -  Malignancy or basal cell carcinoma.&#xD;
&#xD;
          -  Active, serious infections requiring parenteral antibiotic therapy within 15 days&#xD;
             prior to screening.&#xD;
&#xD;
          -  Prior history of significant renal or bone disease.&#xD;
&#xD;
          -  Subjects should avoid giving blood for the duration of this study.&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             investigator, would make the subject unsuitable for the study or unable to comply with&#xD;
             the dosing requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme Moyle, MD, MB, BS, DipGUM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea and Westminster Hospital, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>tenofovir DF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

